Background Inhaled longacting β 2 agonists improve lung function and health status in
symptomatic chronic obstructive pulmonary disease (COPD), whereas inhaled …

Background Long-acting beta-agonists and inhaled corticosteroids are used to treat chronic
obstructive pulmonary disease (COPD), but their effect on survival is unknown. Methods We …

Background: Inhaled corticosteroids (ICSs) and long-acting β2-agonists (LABAs) are used to
treat moderate to severe chronic obstructive pulmonary disease (COPD). Objective: To …

Rationale: Exacerbations of chronic obstructive pulmonary disease (COPD) greatly
contribute to declining health status and the progression of the disease, thereby incurring …

Long-acting β 2 agonist bronchodilators (eg formoterol, salmeterol) are a new interesting
therapeutic option for patients with chronic obstructive pulmonary disease (COPD). In the …

Chronic obstructive pulmonary disease (COPD) is characterized by progressive airflow
limitation and debilitating symptoms. For patients with moderate-to-severe COPD, long …

Background Previous studies have suggested that long-term use of β agonists to treat
chronic obstructive pulmonary disease (COPD) may increase the risk of cardiovascular …

Despite substantial evidence regarding the benefits of combined use of inhaled
corticosteroids and long-acting β2-agonists in asthma, such evidence remains limited for …

Background The efficacy of inhaled corticosteroids in the treatment of chronic obstructive
pulmonary disease (COPD) remains controversial because of a lack of placebo-controlled …

Background: Guidelines recommend inhaled corticosteroids (ICS) as maintenance treatment
for patients with chronic obstructive pulmonary disease (COPD) with a post-bronchodilator …